Scholar Rock Holding Corp (SRRK) Stock
SRRK has an Alpha Score of 48 out of 100 (weak), computed on Apr 15, 2026 from 2 of 4 sub-scores. 6 of the hedge funds AlphaScala tracks reported SRRK in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $23.68M.
What is SRRK's Alpha Score?
How it works →Alpha Score of 48 reflects weak overall profile with strong momentum, poor quality. Based on 2 of 4 signals — score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Apr 15, 2026 · 189 days ago; due for a rescore
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own SRRK?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 431K | $23.68M | -59% |
| Citadel Ken Griffin | 332K | $18.25M | -63% |
| D.E. Shaw David Shaw | 245K | $13.48M | +1573% |
| Renaissance Technologies Jim Simons (founder) | 92K | $5.03M | NEW |
| Millennium Management Israel Englander | 18K | $994.3K | NEW |
| Blackstone | 9K | $509.4K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are SRRK's key statistics?
Key statistics as of Oct 22, 2026
How does SRRK's valuation compare with the Healthcare sector?
| Metric | SRRK | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -236.96% | 9.40% | 92 |
| Return on equity | -159.12% | 11.24% | 99 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Oct 22, 2026). P/E excludes loss-making companies.
SRRK price chart
Powered by TradingViewWhat does Scholar Rock Holding Corp do?
Scholar Rock Holding Corporation is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases where protein growth factor signaling plays a central role. It employs a proprietary platform targeting the transforming growth factor beta (TGFβ) superfamily to create monoclonal antibodies that selectively inhibit precursor activation of these growth factors. Key product candidates include apitegromab, a selective anti-latent myostatin antibody in Phase 3 for spinal muscular atrophy in patients aged two years and older, with additional Phase 2 programs in spinal muscular atrophy for younger patients and facioscapulohumeral muscular dystrophy, plus preclinical efforts in other neuromuscular diseases. The pipeline also features SRK-181 in Phase 1 for immuno-oncology in cancers resistant to checkpoint inhibitors, SRK-373 in preclinical for fibrotic diseases, and SRK-256 in preclinical for iron-restricted anemia. Scholar Rock Holding Corporation operates in the biotechnology sector, addressing neuromuscular disorders, obesity, cancer, fibrosis, and hematology through this novel approach. Founded in 2012 and headquartered in Cambridge, Massachusetts, it manages its activities as a single operating segment dedicated to advancing these investigational therapies.